A proven track record
Jotbody is a biotechnology company founded in 2020 by a group of globally recognized scientists and senior executives with well-documented experience in biotherapeutics development and entrepreneurship. Jotbody is on the cutting edge for the discovery and engineering of nanobodies from camelids and sharks and has completed numerous custom discovery projects for industry and academic institutions with a success rate of 100%. Our cutting-edge technology and global dual sites enable us to deliver innovative solutions to clients in industry and academia. Our growing list of satisfied clients and partners reflects our commitment to scientific excellence, innovation, and customer satisfaction. Whether you need assistance with a specific project or are interested in exploring the potential of nanobodies, we invite you to contact us to learn more about Jotbody.
“It is truly a five-star experience regarding order handling, technical support, and product quality. After trying other vendors for nanobody generation, Jotbody is the one I will definitely recommend to my colleagues” – Bill Wong | VP Preclinical Development, InnoRNA
“I am writing to express my sincere appreciation for the quality of antibody service you provided. I really appreciate your efficient, gracious service, the level of detail, professionalism, and accountability you have demonstrated on my project, and the way you conduct business as a whole.” – Hua Zhang | VP and Chief Scientific Officer, SPH Biotherapeutics
“We achieved successful cell targeting using your nanobody-clicked EVs. Thanks for your continuous support – it has been great working with you” – Anna Cifuentes-Rius | Director Research & Innovation, Exopharm
Products and services
Our exclusive shark platform
Decades have passed since the discovery of the peculiar heavy-chain antibodies in camelids (VHH), followed by the elucidation of the similar, heavy-chain-only structure of sharks' new antigen receptors (vNAR). Both of them share several characteristics such as high stability and solubility, longer than average CDR3 loops, and the presence of non-canonical disulfide linkages sculpting the binding site.
While VHH domains have attracted great interest as biological drugs and proven to be successful in clinical trials, the engineering of vNAR domains for biomedical applications is at an early stage. Despite this, it is abundantly clear that they present a singular molecular framework that can be exploited to develop reagents for scientiﬁc research, disease diagnosis, and/or therapeutic intervention.
Jotbody provides discovery services for nanobodies from immunized and naive libraries. We source the best alpaca livestock in Australia for our immunization program, generating diverse immune responses and high-quality antibodies. Our experienced scientists work closely with clients to deliver tailored solutions and successful outcomes.
Nanobody, also called single-domain antibody, is the variable region isolated from the antigen-binding variable domain (VHH) of camelid heavy chain-only antibody or the variable domain (vNAR) of cartilaginous fish immunoglobulin new antigen receptor (IgNAR). With a size of just 12～15 kDa (2~4 nm), nanobody is the smallest antigen-binding fragment discovered today and holds a plethora of intrinsic advantages over conventional monoclonal antibodies.
Immunized vs naïve libraries
Antibody libraries can be generated from immune hosts who have developed a strong and specific humoral response against the desired target or naïve hosts who have never been challenged with a specific immunogen. Whether you need a partner to develop high-diversity immune libraries for antibody phage display or ready-made naïve antibody libraries, Jotbody offers them all to suit your needs.